Pfizer Inc
Analysis Terminal
AI Sector Synthesis
Pfizer's COVID product revenue is reportedly shrinking, and the company's total revenue has remained flat over the past year. The best case for Pfizer stock suggests that future growth is anticipated from smaller, faster-growing segments of the company, rather than its established medicines or further cost reductions.
Latest Market News
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.
These 6 High-Yield Dividends May Be Too Good to Be True
A fat dividend yield can signal a screaming buy or a slow-motion disaster, and the difference hides in coverage math most investors never check. Six well-known names are flashing the exact warning signs that tend to show up just before a payout gets cut.
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
MBX Biosciences is upgraded to Buy on strong Phase 2 canvuparatide data, Phase 3 path, and cash-rich catalysts. Click for this MBX stock update.
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
Pfizer’s International Chief Just Explained How the Turnaround Actually Works. Here’s Where the Stock Could Go
Key Stats for Pfizer StockCurrent Price: $27. 93Target Price (Mid): ~$29Street Target: ~$29Potential Total Return: ~5%Annualized IRR: ~1.
Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality
Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735. Click for more.
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.
3 Dividend Stocks Trading Cheap Enough to Buy Meaningful Stakes for Under $1,000
AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors nervous.
Pfizer Inc is a leading entity in the Pharmaceuticals sector, headquartered in US.
Professional Notice
Information is for educational purposes only. Market data is sourced via global nodes and is not financial advice.